Partial Mglur5 Antagonists For Treatment Of Anxiety And Cns Disorders

Abstract

Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention. Specific examples of partial MgluR5 antagonists provided include those compounds having the formula: wherein: Z is, independently N or -CH-, provided that one, and only one Z is N; R is halogen (e.g., Br, F and the like), alkyl (e.g., methyl), alkenyl (e.g., CH-CH2, aryl (e.g., phenyl), heterocyclic (e.g., thiophenyl).


Claims
Download PDF
Document Preview
Document History
  • Publication: May 12, 2009
  • Application: Sep 20, 2006
    US US 52387306 A
  • Priority: Sep 20, 2006
    US US 52387306 A
  • Priority: Dec 6, 2005
    US US 74251605 P
  • Priority: Sep 20, 2005
    US US 71829805 P

Download Citation


Sign in to the Lens

Feedback